Importance is a model-assigned 1–5 on published stories, not a market forecast.
Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.
An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.
Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.
Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.
A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.
Mon · 12 Oct · today
Tue · 13 Oct
Fri · 28 Aug
product
Roche reported that Vabysmo demonstrated sustained two-year results in a difficult-to-treat form of neovascular age-related macular degeneration. This is follow-up data on an already-approved product, so it is graded as incremental.
Markets open original ↗
Thu · 27 Aug
earnings
Canadian Solar reported a Q2 2026 loss of $1.40 per share versus a consensus estimate of a $1.01 loss and a year-ago loss of $0.08. Revenue of $1.21 billion topped the $1.17 billion consensus but fell 28.7% from $1.69 billion a year earlier, and solar modules recognized as revenue totaled 3.1 gigawatts, down 25% year over year. The company guided Q3 revenue to $1.30-$1.50 billion with gross margin of 13.5%-15.5%, below the $1.65 billion Q3 consensus cited in the article.
Markets open original ↗
product
RTX's Raytheon business completed a $50 million, 17,000 square-foot expansion of its Forest, Mississippi plant, bringing the site to 445,000 square feet of manufacturing space. The facility builds electronic warfare and radar systems including Next Generation Jammer Mid-Band pods for the U.S. Navy and the Australian government, and the expansion is expected to add 100 high-skill positions by 2028.
Markets open original ↗
partnership
argenx announced it has completed its acquisition of Forte Biosciences, Inc. Forte is not in this universe, so it is not listed as a counterparty. Consideration is not stated in the headline and is not reproduced here.
Markets open original ↗
product
Tezspire, co-developed by AstraZeneca and Amgen, hit its endpoints in a Phase 3 trial in eosinophilic esophagitis, opening a potential new indication.
Markets open original ↗
